Investment Institute
Macroeconomic Research

China: Navigating its way out of 'Zero-Covid'

  • 05 May 2022 (7 min read)

Key Points

  • A vicious Omicron flareup is giving Beijing’s ‘Zero-Covid’ policy its toughest test since the onset of the pandemic. Although the strategy has proven effective to date in confining infections to a few places, the enormous economic and social costs have raised doubts about its sustainability
  • The prospects of continuing economic and social disruption may have shaken Beijing’s confidence in the strategy and could, in our view, prompt tangible changes as soon as Shanghai’s situation stabilises
  • The adjustment won’t be a sudden leap to full liberalisation – due to health and political considerations – but a gradual and managed shift away from draconian lockdowns to more targeted containment, vaccines, self-testing and protecting the vulnerable
  • While conceptually possible, striking the right balance will be difficult in practice. Doing too little may not help the economy, while going too far could risk losing control of the pandemic, incurring vast damages on the social and macro system
  • Beijing therefore has to walk a fine line to seek a viable solution. Our base case assumes the right balance will be achieved and growth recovers in the second half of the year. Failure to do so could see the economy struggle more than it did in 2020
Download the Insight
Download report (350.87 KB)

Related Articles

Macroeconomic Research

India’s economy: A compelling growth and investment story but challenges remain

  • by Danny Richards
  • 11 June 2024 (10 min read)
Macroeconomic Research

Eurozone corporate profits outlook: How they could influence the ECB

Macroeconomic Research

Will the US presidential election endanger an investment boom?


    This document is for informational purposes only and does not constitute investment research or financial analysis relating to transactions in financial instruments as per MIF Directive (2014/65/EU), nor does it constitute on the part of AXA Investment Managers or its affiliated companies an offer to buy or sell any investments, products or services, and should not be considered as solicitation or investment, legal or tax advice, a recommendation for an investment strategy or a personalized recommendation to buy or sell securities.

    It has been established on the basis of data, projections, forecasts, anticipations and hypothesis which are subjective. Its analysis and conclusions are the expression of an opinion, based on available data at a specific date.

    All information in this document is established on data made public by official providers of economic and market statistics. AXA Investment Managers disclaims any and all liability relating to a decision based on or for reliance on this document. All exhibits included in this document, unless stated otherwise, are as of the publication date of this document.

    Furthermore, due to the subjective nature of these opinions and analysis, these data, projections, forecasts, anticipations, hypothesis, etc. are not necessary used or followed by AXA IM’s portfolio management teams or its affiliates, who may act based on their own opinions. Any reproduction of this information, in whole or in part is, unless otherwise authorised by AXA IM, prohibited.

    Back to top